Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

The Liabilities of Pharmacovigilance Activities

Posted on June 21st, 2017 by in Pharmacovigilance

There is always a risk that any Pharmacovigilance (PV) activity, even executed with the highest business and ethical standards, and with the highest compliance results, could be challenged, sometimes many years later. As a member of a PV team, you may have to one day justify your actions in front of a group of plaintiff’s lawyers, Continue reading “The Liabilities of Pharmacovigilance Activities” »

So-Called Rare Diseases Are Too Common to Ignore

Posted on June 19th, 2017 by in Pharma R&D

It’s time to re-think our attitude towards rare diseases. Even though relatively few people suffer from any given rare disease, there are so many of these maladies that it’s a surprisingly large swath of the population that is actually victimized by them. Continue reading “So-Called Rare Diseases Are Too Common to Ignore” »

Connecting the data sources to understand the safety of bioactivities

Posted on June 16th, 2017 by in Pharma R&D

Earlier this week, I was in Berlin, Germany speaking for the Elsevier Professional Services team at the Drug Discovery Summit (Monday, June 12, 15:30) at the Hotel Palace Berlin on informatics analyses to provide early warning for clinical issues from bioassay results. Continue reading “Connecting the data sources to understand the safety of bioactivities” »

What Are Best Practices in Literature Monitoring for Top-performing Pharma Companies?

Posted on June 14th, 2017 by in Pharmacovigilance

The health and safety of patients is of utmost concern to pharmaceutical companies, and strict regulatory requirements ensure that safety standards remain high. But pharmacovigilance becomes an ever more difficult and overwhelming practice Continue reading “What Are Best Practices in Literature Monitoring for Top-performing Pharma Companies?” »

  1. 1
  2. 2
  3. 3